Canadian inhaler tracking and training start-up BreatheSuite has announced the completion of a $1.2 million financing round and said that it intends to use the funds for expanded distribution of its MDI add-on device in North America and for development of additional inhaler tracking products. The company conducted patient testing of its MDI add-on and associated app in the US in 2020.
BreatheSuite CEO Brett Vokey said, “Amidst all of its challenges, 2020 was a phenomenal year for BreatheSuite. We were able to expand our team, secure international partnerships to offer devices to patients, and complete invaluable research both within Canada and the United States. This investment is a testament to the progress we’ve made during a year that brought unprecedented change. We’re hopeful that the increased adoption of digital health technologies will continue in the future, setting a new standard for virtual healthcare. . . . It is amazing to think about how far we’ve come, but all the more exciting to focus on our future. We want to set the standard for connected healthcare worldwide in asthma & COPD, and are excited to do it right here in our province.”
Read the BreatheSuite press release.
